Partner Teresa Reguly will speak at The Canadian Institute webinar titled “PMPRB Modernization and New Regulations: How to Navigate the Transition into a New Regulatory Regime for Drug Pricing in Canada” on July 27.
With new amendments to Patented Medicines Regulations set to come to force at the start of 2022, manufacturers will have to determine how drugs are currently being reviewed, and how to achieve pricing compliance. Teresa along with other panelists will discuss the status of regulations and PMPRB’s guidelines, the impact to drugs that are currently on the market in Canada, assess how pipeline drugs will be reviewed after the implementation of the new framework, and more.
You can watch this session by registering on The Canadian Institute’s website.
